SCHEDULE 13D/A: Apeiron Group Boosts ATAI Stake to 24% Amid Offering

Apeiron Investment Group and related entities increased their beneficial ownership in ATAI Life Sciences N.V. to 24.0% following a share conversion and a new lock-up agreement.

Summary

• Christian Angermayer and affiliated reporting persons collectively beneficially own 56,551,379 Ordinary Shares of ATAI Life Sciences N.V.
• This represents approximately 24.0% of the Issuer's Ordinary Shares outstanding.
• The ownership percentage is calculated based on 235,969,597 Ordinary Shares outstanding as of October 16, 2025.
• Apeiron Investment Group Ltd. received an additional 2,367,200 Ordinary Shares from the conversion of previously disclosed convertible promissory notes.
• Christian Angermayer's beneficial ownership includes 1,339,663 vested options exercisable at $5.68 per Ordinary Share.
• Apeiron Investment Group Ltd. entered into a 90-day lock-up agreement with Jefferies LLC, the underwriter of a recent offering, restricting the sale of ATAI shares.
• ATAI Life Sciences N.V. closed a registered offering of 23,725,000 Common Shares at $5.48 per share, generating approximately $130 million in gross proceeds.

Sentiment

Score: 7

Explanation: The filing indicates strong insider commitment through increased beneficial ownership and a lock-up agreement, alongside a successful capital raise, which are generally positive signals for the company's stability and funding.

Positives

• Increased beneficial ownership by a significant investor group, led by Christian Angermayer, signals strong confidence in ATAI Life Sciences N.V.'s future.
• The 90-day lock-up agreement by Apeiron Investment Group Ltd. provides short-term stability by preventing a large block of shares from being sold on the open market.
• The successful completion of a registered offering raising $130 million provides capital for the Issuer's operations and strategic initiatives.

Risks

• The expiration of the 90-day lock-up period could lead to increased selling pressure if Apeiron Investment Group Ltd. decides to divest a portion of its holdings.
• The exercise price of Christian Angermayer's vested options ($5.68 per share) is close to the recent offering price ($5.48 per share), indicating potential for future dilution or selling pressure if exercised and sold.

Future Outlook

The lock-up agreement indicates a period of stability for the Issuer's share price from a major shareholder for 90 days following the offering. The capital raise provides funding for future operations.

Industry Context

Increased insider ownership by a prominent investor like Christian Angermayer, known for his involvement in the psychedelic-based therapeutics space, can be viewed positively by the market, signaling continued commitment to ATAI Life Sciences N.V. The capital raise is consistent with the funding needs of biopharmaceutical companies in the development stage.

Comparison to Industry Standards

• NA

Related Party Transactions

• Apeiron Investment Group Ltd., a reporting person and entity controlled by Christian Angermayer, received 2,367,200 Ordinary Shares upon the conversion of previously disclosed convertible promissory notes of the Issuer.

Stakeholder Impact

• Shareholders: Increased insider ownership may instill confidence. The lock-up agreement provides short-term price stability by restricting a major shareholder from selling shares.
• Company: The successful capital raise provides significant funding for ongoing operations and strategic development.

Next Steps

• Expiration of the 90-day lock-up period for Apeiron Investment Group Ltd. (approximately January 18, 2026).

Key Dates

Recommendation

This filing primarily details a change in beneficial ownership and a lock-up agreement following a capital raise. While increased insider ownership and a lock-up can be seen as positive signals of confidence and short-term stability, the filing does not provide sufficient operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It confirms a significant investor's continued commitment and a recent capital infusion, suggesting a 'hold' position while awaiting further operational updates.

Keywords

ATAI Life Sciences, Apeiron Investment Group, Christian Angermayer, Beneficial Ownership, Schedule 13D, Lock-up Agreement, Capital Raise, Convertible Notes, Biopharmaceutical, Investment